NCT06756269 2025-12-17
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 2 Recruiting
Shanghai Bovax Biotechnology Co., Ltd.
Zydolab - Institute of Cytology and Immune Cytochemistry
Shanghai Bovax Biotechnology Co., Ltd.
Shanghai Bovax Biotechnology Co., Ltd.
Shanghai Bovax Biotechnology Co., Ltd.